Evofem Biosciences Inc. announced an amendment to its existing agreement with Adjuvant Global Health Technology Fund, adjusting the repayment timeline for certain convertible notes. The updated terms specify that the notes will be due either six months from the amendment date, upon a change of control, or in the event of acceleration. Prepayment is restricted for six months following the amendment unless Adjuvant approves otherwise.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018454), on October 17, 2025, and is solely responsible for the information contained therein.